Tris Pharma's CRL for narcolepsy drug; Agenus abandons Phase 3 CRC trial
RegulatoryCRLJemperliPadcevNegative
AI Analysis
Summary
Tris Pharma received a Complete Response Letter from the FDA for its narcolepsy drug, while Agenus announced discontinuation of a Phase 3 colorectal cancer trial.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
FDA issued Complete Response Letter for Tris Pharma's narcolepsy drug; additional information necessary
Importance:8/10
Sentiment:
-0.90
FDA rejectionCRLnarcolepsycolorectal cancerPhase 3 discontinuation
Read the original article
Published by Endpoints News on July 13, 2026 2:30 PM